| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
|
Circulation
|
2002
|
2.07
|
|
2
|
Endothelial dysfunction as a target for prevention of cardiovascular disease.
|
Diabetes Care
|
2009
|
1.91
|
|
3
|
Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.
|
Br J Clin Pharmacol
|
2009
|
1.81
|
|
4
|
Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction.
|
Circulation
|
2004
|
1.65
|
|
5
|
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy.
|
J Clin Endocrinol Metab
|
2003
|
1.61
|
|
6
|
Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates Ang II-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats.
|
J Hypertens
|
2002
|
1.52
|
|
7
|
Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients.
|
Circulation
|
2009
|
1.49
|
|
8
|
Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension.
|
Hypertension
|
2003
|
1.43
|
|
9
|
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.
|
JAMA
|
2004
|
1.40
|
|
10
|
Tissue-type plasminogen activator release in healthy subjects and hypertensive patients: relationship with beta-adrenergic receptors and the nitric oxide pathway.
|
Hypertension
|
2008
|
1.39
|
|
11
|
The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients.
|
J Am Coll Cardiol
|
2003
|
1.33
|
|
12
|
Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis.
|
J Clin Endocrinol Metab
|
2006
|
1.29
|
|
13
|
Endothelium-dependent contractions and endothelial dysfunction in human hypertension.
|
Br J Pharmacol
|
2009
|
1.27
|
|
14
|
The eye and the heart.
|
Eur Heart J
|
2013
|
1.18
|
|
15
|
Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling.
|
Hypertension
|
2003
|
1.15
|
|
16
|
Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
|
Can J Physiol Pharmacol
|
2005
|
1.12
|
|
17
|
Hydrogen sulphide: novel opportunity for drug discovery.
|
Med Res Rev
|
2010
|
1.11
|
|
18
|
Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.
|
Drugs
|
2002
|
1.11
|
|
19
|
Hypertension and endothelial dysfunction: therapeutic approach.
|
Curr Vasc Pharmacol
|
2012
|
1.06
|
|
20
|
Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients.
|
J Am Coll Cardiol
|
2006
|
1.05
|
|
21
|
Inhibition of adenosine deaminase attenuates inflammation in experimental colitis.
|
J Pharmacol Exp Ther
|
2007
|
1.01
|
|
22
|
Endothelium, aging, and hypertension.
|
Curr Hypertens Rep
|
2006
|
0.97
|
|
23
|
The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors.
|
J Pharmacol Exp Ther
|
2010
|
0.93
|
|
24
|
Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment.
|
Hypertension
|
2004
|
0.91
|
|
25
|
Poor sleep quality and resistant hypertension.
|
Sleep Med
|
2013
|
0.91
|
|
26
|
Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy.
|
J Clin Endocrinol Metab
|
2006
|
0.88
|
|
27
|
Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D.
|
J Renin Angiotensin Aldosterone Syst
|
2013
|
0.86
|
|
28
|
2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy.
|
High Blood Press Cardiovasc Prev
|
2013
|
0.86
|
|
29
|
Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II.
|
J Hypertens
|
2004
|
0.85
|
|
30
|
The ageing endothelium, cardiovascular risk and disease in man.
|
Exp Physiol
|
2008
|
0.85
|
|
31
|
Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism.
|
J Hypertens
|
2003
|
0.84
|
|
32
|
Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension.
|
Curr Hypertens Rep
|
2009
|
0.84
|
|
33
|
Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent bystander?
|
Eur Heart J
|
2010
|
0.84
|
|
34
|
Chronic treatment with long-acting nifedipine reduces vasoconstriction to endothelin-1 in essential hypertension.
|
Hypertension
|
2006
|
0.82
|
|
35
|
[Obesity and endothelial dysfunction].
|
G Ital Cardiol (Rome)
|
2006
|
0.81
|
|
36
|
Endothelium-dependent vasodilation and carotid artery wall remodeling in athletes and sedentary subjects.
|
Atherosclerosis
|
2005
|
0.80
|
|
37
|
Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment.
|
PLoS One
|
2013
|
0.80
|
|
38
|
Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension.
|
Hypertension
|
2003
|
0.79
|
|
39
|
Characterisation of hypertensive patients with improved endothelial function after dark chocolate consumption.
|
Int J Hypertens
|
2013
|
0.78
|
|
40
|
Nitric oxide modulates tissue plasminogen activator release in normotensive subjects and hypertensive patients.
|
Hypertension
|
2007
|
0.78
|
|
41
|
Haptoglobin deficiency determines changes in adipocyte size and adipogenesis.
|
Adipocyte
|
2012
|
0.77
|
|
42
|
Hypertension and cardiometabolic risk factors.
|
Int J Hypertens
|
2013
|
0.77
|
|
43
|
[Strategies for improving blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. 2012 Position paper of the Italian Society of Hypertension].
|
G Ital Cardiol (Rome)
|
2012
|
0.77
|
|
44
|
Vascular reactivity in patients with undifferentiated connective tissue diseases.
|
Atherosclerosis
|
2008
|
0.77
|
|
45
|
Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1.
|
Br J Pharmacol
|
2013
|
0.77
|
|
46
|
Which endothelium-derived factors are really important in humans?
|
Biol Chem
|
2006
|
0.77
|
|
47
|
Aging and hypertension: what about the endothelium?
|
J Hypertens
|
2006
|
0.76
|
|
48
|
Exogenous ghrelin on nitric oxide-endothelin 1 imbalance in metabolic syndrome: can we kill 2 birds with 1 stone?
|
Hypertension
|
2009
|
0.76
|
|
49
|
Renal artery denervation for treating resistant hypertension : definition of the disease, patient selection and description of the procedure.
|
High Blood Press Cardiovasc Prev
|
2013
|
0.75
|
|
50
|
Selective renin inhibition in obese hypertensive patients: perspectives from tissue penetration.
|
J Hypertens
|
2012
|
0.75
|
|
51
|
Response to Endothelial nitric oxide synthase, cyclooxygenase-2, and essential hypertension: is there an interaction?
|
Hypertension
|
2013
|
0.75
|
|
52
|
Target organ damage in hypertension.
|
Int J Hypertens
|
2012
|
0.75
|
|
53
|
Low birth weight and insulin resistance: can capillary recruitment predict hypertension development?
|
J Hypertens
|
2002
|
0.75
|
|
54
|
Device-based therapies for resistant hypertension.
|
Curr Pharm Des
|
2013
|
0.75
|
|
55
|
Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects.
|
J Hypertens
|
2006
|
0.75
|
|
56
|
[Renal denervation for the treatment of resistant hypertension: definition, patient selection and description of the procedure. 2012 Position paper of the Italian Society of Hypertension].
|
G Ital Cardiol (Rome)
|
2012
|
0.75
|
|
57
|
Therapeutic implications of recent megatrials: in favor of old drugs.
|
J Nephrol
|
2007
|
0.75
|
|
58
|
Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants.
|
Curr Pharm Des
|
2014
|
0.75
|
|
59
|
[Clinical significance of the assessment of endothelial function].
|
Ital Heart J Suppl
|
2004
|
0.75
|
|
60
|
Blood pressure and vascular alterations with growth in childhood.
|
Curr Pharm Des
|
2011
|
0.75
|
|
61
|
Highlights from International Congress : The XI Forum on the Renin-Angiotensin System, Capri, Italy, 11-12 April, 2008.
|
High Blood Press Cardiovasc Prev
|
2008
|
0.75
|
|
62
|
National survey on excellence centers and reference centers for hypertension diagnosis and treatment: geographical distribution, medical facilities and diagnostic opportunities.
|
High Blood Press Cardiovasc Prev
|
2013
|
0.75
|